Shawn M. Cross's most recent trade in Pacira BioSciences Inc was a trade of 12,941 Common Stock done at an average price of $16.4 . Disclosure was reported to the exchange on April 23, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.45 per share. | 23 Apr 2026 | 12,941 | 118,282 (0%) | 0% | 16.4 | 212,879 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Apr 2026 | 12,941 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.16 per share. | 23 Apr 2026 | 12,941 | 105,341 (0%) | 0% | 25.2 | 325,596 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.45 per share. | 20 Apr 2026 | 7,714 | 113,055 (0%) | 0% | 16.4 | 126,895 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2026 | 7,714 | 167,286 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.14 per share. | 20 Apr 2026 | 7,714 | 105,341 (0%) | 0% | 25.1 | 193,930 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2026 | 2,845 | 164,441 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 20 Apr 2026 | 2,845 | 105,341 (0%) | 0% | 25.0 | 71,153 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.45 per share. | 20 Apr 2026 | 2,845 | 108,186 (0%) | 0% | 16.4 | 46,800 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2026 | 1,500 | 162,941 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 20 Apr 2026 | 1,500 | 105,341 (0%) | 0% | 25.0 | 37,515 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.45 per share. | 20 Apr 2026 | 1,500 | 106,841 (0%) | 0% | 16.5 | 24,675 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2026 | 49,091 | 105,341 (0%) | 0% | 0 | Common Stock | |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.45 per share. | 09 Dec 2025 | 15,896 | 72,146 (0%) | 0% | 16.4 | 261,489 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2025 | 15,896 | 184,104 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.03 per share. | 09 Dec 2025 | 15,896 | 56,250 (0%) | 0% | 25.0 | 397,877 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2025 | 9,104 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.14 per share. | 09 Dec 2025 | 9,104 | 56,250 (0%) | 0% | 25.1 | 228,875 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.45 per share. | 09 Dec 2025 | 9,104 | 65,354 (0%) | 0% | 16.5 | 149,761 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.09 per share. | 10 Nov 2025 | 12,060 | 56,250 (0%) | 0% | 22.1 | 266,405 | Common Stock |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.38 per share. | 31 Oct 2025 | 6,690 | 68,310 (0%) | 0% | 21.4 | 143,032 | Common Stock |
| Cyclo Therapeutics Inc | Shawn M. Cross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 28,597 | 136,346 | - | 0 | Common Stock | |
| Cyclo Therapeutics Inc | Shawn M. Cross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2024 | 17,228 | 107,749 | - | 0 | Common Stock | |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2024 | 75,000 | 75,000 (0%) | 0% | 0 | Common Stock |